Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
TUCSON, Ariz. , Sept. 21, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will present in a fireside chat in Cantor Fitzgerald’s Virtual Global Healthcare
Toggle Summary HTG Molecular Diagnostics to Present at H.C. Wainwright’s 23rd Annual Global Investment Conference
TUCSON, Ariz. , Sept. 08, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that company management will participate in H.C. Wainwright’s 23rd Annual Global Investment Conference ,
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2021 Results
Call scheduled for today, August 12, at 4:30pm ET TUCSON, Ariz. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported its financial results for the quarter ended June 30, 2021
Toggle Summary HTG’s New HTG Transcriptome Panel Launched with Commercial Availability in the U.S. and Europe
HTG Transcriptome Panel designed to measure approximately 20,000 mRNA targets using the  HTG EdgeSeq technology Intended to serve as one of the technological cornerstones for the  recently announced HTG Therapeutics Business Unit A third white paper highlighting the HTG Transcriptome Panel’s
Toggle Summary HTG Molecular Diagnostics to Announce Second Quarter 2021 Financial Results and Host Conference Call on Thursday, August 12
TUCSON, Ariz. , Aug. 03, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2021 after the market close on

Stock Chart

SEC Filings

Filing date Description

Securities offered to employees pursuant to employee benefit plans

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities